Influence of Angiotensin Converting Enzyme (ACE) Genotype on Lung Diffusion in Heart Failure
Influence of ACE Genotype on Lung Diffusion at Rest and After Fluid Overload in Heart Failure Patients Treated With ACE-inhibitors
1 other identifier
interventional
100
1 country
1
Brief Summary
In patients with chronic heart failure ACE-inhibitor treatment improves lung diffusion and prevents pulmonary edema after fluid overload. In the western country, 3 population types of ACE genotypes exist (DD, ID, II). It is unknown whether the ACE genotype influences the response to fluid overload in ACE-inhibitor treated chronic heart failure patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Aug 2006
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2006
CompletedFirst Submitted
Initial submission to the registry
August 4, 2006
CompletedFirst Posted
Study publicly available on registry
August 7, 2006
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2013
CompletedJanuary 28, 2016
January 1, 2016
7.3 years
August 4, 2006
January 27, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Possible identification of a genetic pattern responsible for different responses to ACE-inhibition during fluid overload in heart failure
Third day
Secondary Outcomes (2)
Influence of ACE-genotype on exercise capacity
Third day
Influence of ACE-genotype on lung function
Third day
Study Arms (1)
CMPD patients
EXPERIMENTALPatients with CMPD with evaluation of ACE I/D polymorphism
Interventions
Eligibility Criteria
You may qualify if:
- New York Heart Association (NYHA) class I and II heart failure
- Chronic ACE-inhibitor treatment
You may not qualify if:
- Aspirin treatment in the previous 2 months
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Centro Cardiologico Monzino
Milan, 20138, Italy
Related Publications (2)
Agostoni P, Cattadori G, Bianchi M, Wasserman K. Exercise-induced pulmonary edema in heart failure. Circulation. 2003 Nov 25;108(21):2666-71. doi: 10.1161/01.CIR.0000097115.61309.59. Epub 2003 Oct 27.
PMID: 14581402BACKGROUNDGuazzi M, Marenzi G, Alimento M, Contini M, Agostoni P. Improvement of alveolar-capillary membrane diffusing capacity with enalapril in chronic heart failure and counteracting effect of aspirin. Circulation. 1997 Apr 1;95(7):1930-6. doi: 10.1161/01.cir.95.7.1930.
PMID: 9107182BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Piergiuseppe Agostoni, MD.PhD
Centro Cardiologico Monzino
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- MD PhD
Study Record Dates
First Submitted
August 4, 2006
First Posted
August 7, 2006
Study Start
August 1, 2006
Primary Completion
December 1, 2013
Study Completion
December 1, 2013
Last Updated
January 28, 2016
Record last verified: 2016-01